Bausch + Lomb Corp's stock has seen a notable uptick, reflecting positive sentiment in the ophthalmology devices market.
Shares of Bausch + Lomb Corp (BLCO.TO) closed up 2.32% at CA$23.39 in the latest trading session, buoyed by optimism surrounding the ophthalmology devices market. The company is strategically positioned to capitalize on growing demand for innovative eye care solutions, particularly as the market is projected to expand significantly in the coming years.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.09B
52W high
$25.70
52W low
$18.24
1W change
-1.68%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to fall 17.7% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$18.82
-17.7% Upside
Current Price
C$22.86
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
32.3%
Annualized
90-Day Vol
31.0%
Annualized
Trend (90d)
+0.9%
Annualized drift
90d Mean
C$22.94
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$22.89 | C$20.47 โ C$25.58 |
| 60 trading days | C$22.91 | C$19.57 โ C$26.81 |
| 90 trading days | C$22.94 | C$18.91 โ C$27.81 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep an eye on Bausch + Lomb's developments in the ophthalmology sector, as increasing demand for advanced eye care solutions may drive further growth.
Market Cap: CA$8.09 Billion
Bausch + Lomb's market cap reflects its significant presence in the eye care industry, underscoring its potential for growth amidst increasing demand for ophthalmic solutions.
Bull case
The ophthalmology devices market is expected to grow from $56.61 billion in 2025 to $63.23 billion in 2026. This growth is driven by an aging population and a rise in eye disorders. Bausch + Lomb's recent acquisitions and focus on development position it well to take advantage of this trend.
Bear case
Despite the positive momentum, Bausch + Lomb has faced challenges in drug development, which could pose risks. For instance, the discontinuation of its glaucoma eye drop program highlights the unpredictability of pharmaceutical pipelines.
Market Growth in Ophthalmology
The ophthalmology devices market is projected to grow from $56.61 billion in 2025 to $63.23 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.7%. This growth is fueled by factors like an aging population, increased healthcare spending, and a rise in eye disorders. Bausch + Lomb's focus on innovation and expansion in this sector positions it favorably to capture market share.
Strategic Developments by Bausch + Lomb
Bausch + Lomb's recent acquisition of AcuFocus, Inc. enhances its surgical portfolio, especially in cataract and intraocular lens solutions. The company's diverse pipeline, which includes over 60 assets under development, shows its commitment to innovation and long-term growth. Despite recent setbacks with its glaucoma treatment, the company remains focused on advancing other promising candidates.
Investor Sentiment and Future Outlook
With shares rising, investor sentiment appears optimistic about Bausch + Lomb's potential in the growing ophthalmology market. However, investors should stay cautious of the risks tied to drug development and market fluctuations. Staying updated on the company's strategic moves and market trends will be crucial for making informed investment decisions.
Advertisement
